|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-10-11
|
|
pubmed:abstractText |
Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted; 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-1048
|
|
pubmed:author |
pubmed-author:AndreassonBjörnB,
pubmed-author:BirgegårdGunnarG,
pubmed-author:BruneMatsM,
pubmed-author:KuttiJackJ,
pubmed-author:LazarevicVladimirV,
pubmed-author:LeBlancKatarinaK,
pubmed-author:MalmClaesC,
pubmed-author:MerupMatsM,
pubmed-author:NahiHarethH,
pubmed-author:NilssonLarsL,
pubmed-author:Swedish Group for Myeloproliferative Disorders
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
135
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
367-73
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16972981-Adult,
pubmed-meshheading:16972981-Antilymphocyte Serum,
pubmed-meshheading:16972981-Antineoplastic Agents,
pubmed-meshheading:16972981-Busulfan,
pubmed-meshheading:16972981-Child, Preschool,
pubmed-meshheading:16972981-Cyclophosphamide,
pubmed-meshheading:16972981-Female,
pubmed-meshheading:16972981-Graft vs Host Disease,
pubmed-meshheading:16972981-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16972981-Humans,
pubmed-meshheading:16972981-Immunosuppressive Agents,
pubmed-meshheading:16972981-Lymphocyte Transfusion,
pubmed-meshheading:16972981-Male,
pubmed-meshheading:16972981-Middle Aged,
pubmed-meshheading:16972981-Postoperative Complications,
pubmed-meshheading:16972981-Primary Myelofibrosis,
pubmed-meshheading:16972981-Spleen,
pubmed-meshheading:16972981-Time Factors,
pubmed-meshheading:16972981-Treatment Outcome,
pubmed-meshheading:16972981-Vidarabine,
pubmed-meshheading:16972981-Whole-Body Irradiation
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
|
|
pubmed:affiliation |
Department of Haematology, Karolinska University Hospital, Stockholm, Sweden. mats.merup@ki.se
|
|
pubmed:publicationType |
Journal Article
|
